RonFarms
Posted - 9 hours ago
$CADL Could $NVS buy us? Do they have enough money?
DiamondCapital
Posted - 11 hours ago
$CVKD Also another one of their directors, Steven Zelenkofske held leadership positions at $BSX $NVS $AZN
padd1
Posted - 12 hours ago
$AMPH Short report on Amphastar Pharmaceuticals just came out because apparently competitor Viatris has received FDA approval, which now poses major competition to Amphastar's only major product.
$VTRS $TEVA $NVS
AshHydrogen
Posted - 1 day ago
$PLTR RETAIL PUT are the C Suite’s from the Palantir BOOTCAMPS buying the COMMONS!!! $bp $len $NVS $LOW just to name a few!!! Aka 1,000’s of HODL!!! Story below… https://sih-st-charts.stocktwits-cdn.com/production/original_581698413.jpeg
JuggernautRaider
Posted - 1 day ago
$TNXP @Risky2 and @biotechlovers :
I posted about Tonix’s recent hires which prove they’re anticipating an approval and planning for a launch.
This is an exciting New Jersey biotechnology located not far from $ABBV, $BMY , $GILD , and $NVS ‘s offices.
If approved, this stock will skyrocket - will they stay independent or be acquired by @BigPharma??? https://www.linkedin.com/posts/jeff-conroy-80a39323_tonix-pharmaceuticals-announces-expansion-activity-7274428825323597824-CWeS?utm_source=share
Soder123
Posted - 3 days ago
You have to check out the Swedish company Diamyd. Great things are currently happening. $SNY $LLY $NVO $NVS $PFE
look2theblue
Posted - 4 days ago
$BLUE Just announce the PRV was received so we can sell it for $100m to $NVS and/or announce a renegotiated agreement with Hercules Capital $HTGC . Then give us updated patient numbers and profitably projection for early next year. A Trifecta. Shorts are in deep here, now is the time for management to generate a $GME type squeeze... Let's get it done!
Quantumup
Posted - 4 days ago
Morgan Stanley⬆️upgraded $PTCT to an Overweight (from Equalweight) rating and a $67 price target, says in its view the current set up for PTC Therapeutics is much more favorable than a year ago: $NVS Sentiment reached a low in late 2023 after the company announced regulatory headwinds for nearly every program in its pipeline. However, there have been multiple recent positive developments in 2024, including Kebilidi approval, the $150M sale of the priority review voucher (PRV), and a global license and collaboration agreement with Novartis for PTC518 in Huntington's disease, including $1B cash upfront at closing in 1Q25. With reduced uncertainty in the pipeline programs, we think the areas of focus for investors is more straightforward for the new year. Our PT increases to $67 (from $45) after modeling ~$300M in risk-adjusted revenues for PTC518 and $1.9B in development/sales milestones, as well as US revenues for Kebilidi and proceeds from the $150M PRV.
SparkyReturns
Posted - 5 days ago
$GILD You might want to check out ICU. Device will soon be in hospital ICUs everywhere as new standard of care. Unique device treats chronic kidney disease, sepsis and other conditions involving hyperinflammation/ cytokine storms. FDA has granted multiple Breakthrough Device Designations (BDDs). FDA has funded grants because data is so good! Humanitarian device exemption granted for kids, and ICU is rolling it out to hospitals now, have 3 hospitals, and 12 more at hospital Internal Review Board stage. Each hospital will generate hundreds of thousands of revenue each quarter. Adult use trials ongoing, FDA also likely to fast track adult indication which multiplies TAM and revenue. Additional indications coming in future to be funded by then-cash-flow. Investors spooked by prior dilutions have unfairly driven down price, huge opportunity. Company recently raised TAM from 1B to $25-33B. Yes you read that right, up to $33 Billion. Current market cap 9.3M! Cheers! $REGN $GSK $MRNA $NVS
DNAedit
Posted - 5 days ago
$FATE meet Andrew Henry. 8 months at Fate. 20+ years of clinical trial experience including 11 years at $NVS Novartis. Excited to see trials ramp up after 3 successful patients. https://www.linkedin.com/in/andrew-henry-8b59255/
raleigh_trader
Posted - 5 days ago
$NVS incredible value here. Novartis is having a fantastic year
Doji_Candle
Posted - 6 days ago
$PFE $MRK $NVS $AMGN we all need drugs to sustain quality of life. BTD opportunity in many of these names.
DiamondCapital
Posted - 1 week ago
Also another board member of $CVKD Steven Zelenkofske held leadership positions at $BSX, $NVS, $AZN
SenefAS
Posted - 1 week ago
Let’s go Seres it’s time to shine… 77% relative risk reduction in bacterial bloodstream infections versus placebo What’s the next step Fast track, partnership ? 🤔 $MCRB $NSRGY $NVS $MRK $JNJ
DonCorleone77
Posted - 1 week ago
$NVS Novartis says longer-term data for Scemblix 'reinforce superior efficacy' Novartis announced "positive," longer-term results from the pivotal Phase 3 ASC4FIRST trial with Scemblix showing superior major molecular response rates at week 96. The study compared the MMR rate of Scemblix to investigator-selected standard-of-care tyrosine kinase inhibitors and to imatinib alone in adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase at the week 96 evaluation, the study's key secondary endpoints. The longer-term results showed an increasing difference in Scemblix MMR rate vs. SoC, vs. imatinib and vs. 2G TKIs. Results were presented at the 66th American Society of Hematology Annual Meeting & Exposition. The median follow-up was 2.2 years for Scemblix and investigator-selected SoC TKIs1. Over 22% more patients treated with once-daily Scemblix achieved MMR at week 96 vs. all investigator-selected SoC TKIs, and nearly 30% more patients achieved MMR at week 96 vs. imatinib alone. The Scemblix MMR rate was 15.1% higher vs. 2G TKIs. Patients treated with Scemblix also achieved deeper rates of molecular responses compared with investigator-selected SoC TKIs, the company reported. "These 96-week results are very encouraging for clinicians who aspire to obtain a balance of efficacy and tolerability profiles to help newly diagnosed adult CML patients achieve and maintain treatment goals," said Jorge Cortes, M.D., Director, Georgia Cancer Center. "The sustained superior efficacy, deeper and more durable responses, and favorable safety and tolerability profile compared to standard of care TKIs continue to support the promise of Scemblix as a potentially practice-changing treatment option."
Bobby__Slapselrod
Posted - 1 week ago
$ENTO $LLY $NVS I’ve heard merger news wit LLY is going to be discussed
Sc1710
Posted - 1 week ago
$ENTO $LLY $NVS merger play you mean?
Gravy_Trains
Posted - 1 week ago
$ENTO The pipeline is attractive to big pharma like $NVS and $LLY
Tomthefirst
Posted - 1 week ago
@no1patfan @Baruke If you want the best Kart-T trading system, better than that of Novartis $NVS and the competition, then you have to look at $AUTL.
Thestocktraderhubzee
Posted - 1 week ago
WATCHLIST DEC 06 2024
$RIG JP Morgan Upgrades Transocean to Neutral, Announces $5 Price Target
$ACHR Archer Aviation Announced That It Has Entered Into A Multiparty Collaboration Agreement With Key UAE And Abu Dhabi Entities To Advance The Establishment Of Electric Air Taxi Operations In Abu Dhabi
$FUFU BitFuFu Announces November 2024 Production And Mining Operations Update: Says 1,643 BTC Held And 84 BTC Produced From Self-mining Operations In November
$FTRE Baird Downgrades Fortrea Holdings to Neutral, Lowers Price Target to $25
$NVS Novartis Announced Topline Results From The APPULSE-PNH Phase 3B Study Of Twice-daily Oral Monotherapy Fabhalta (Iptacopan) In Paroxysmal Nocturnal Hemoglobinuria Patients Who Were Switched From Anti-C5 Therapies, After 24 Weeks Of Treatment With Fabhalta, The Average Hb Level Improved Versus Baseline
DonCorleone77
Posted - 1 week ago
$NVS Novartis reports new Phase 3B data for Fabhalta Novartis announced positive topline results from APPULSE-PNH, a Phase IIIB study evaluating the efficacy and safety of twice-daily oral monotherapy Fabhalta in adult patients with paroxysmal nocturnal hemoglobinuria who were switched from anti-C5 therapies. After 24 weeks of treatment with Fabhalta, the average Hb level improved versus baseline. In the study, the safety profile of Fabhalta monotherapy was consistent with previously reported data. "These new results add to the body of evidence reinforcing that Fabhalta can benefit both patients previously treated with anti-C5 therapies studied in the APPULSE-PNH and APPLY-PNH trials and complement-inhibitor naive patients studied in the APPOINT-PNH trial," said Antonio Risitano, M.D., Ph.D., Chair of the International PNH Interest Group and Head of the Hematology and Hematopoietic Transplant Unit, Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria at the AORN San Giuseppe Moscati, Avellino, Italy, and APPULSE-PNH trial lead investigator. "Treatment goals for patients with PNH have greatly evolved, and we can now aim to resolve signs and symptoms of disease in most patients. It is promising to see this evolution, and we will continue to make progress to best support these patients."
the_goat1
Posted - 1 week ago
$BVAXF The DPX platform proves its strength! New data shows it’s more effective than common adjuvants and even rivals dendritic cells in cancer vaccine development. Plus, DPX has its own immune-stimulating potential, paving the way for breakthrough therapies. 🚀 $LLY $PFE $JNJ $NVS https://ca.finance.yahoo.com/news/biovaxys-shares-data-dpx-immune-120000062.html?guccounter=1
thedatasay20
Posted - 1 week ago
$CADL Paul Manning of PBM owns 7.2% of the companies shares. Some of his other backed companies have been acquired by $NVS 🤔
Gmuskins
Posted - 1 week ago
$NVS $PLTR
AshHydrogen
Posted - 1 week ago
$PLTR Vas from $NVS did a $12 Billion share BUYBACK WITH PALANTIR!!! https://youtu.be/tchD-qz6f_8?si=_6MUA0o3HU2l23po
Tommystar2121
Posted - 1 week ago
$BLUE buy the after market reaction… $nvs will buy out for market share
Tommystar2121
Posted - 1 week ago
$BLUE $NVS 👏👏👏 waiting for it to happen